Gilead Sciences

Gilead Sciences

Community score

+2.65 -55
GLOBAL IMPAAKT UNIVERSE
-0.09
SASB Industry
+1.32
Listing country
+0.13
Ticker: GILD
ISIN: US3755581036
SASB Industry: Biotechnology & Pharmaceuticals
Listing country: United States
Year added: 2018
Market Cap: 107.0bn
Coverage Status: Good
No rank in industry

Incorporated in 1987, Gilead Sciences has established its headquarters in Foster City, California, United States. The company has a diversified business portfolio with a strong focus on five key health categories: antiviral products, other infectious diseases, cardiovascular conditions, inflammation and respiratory diseases, as well as hematology and oncology. Some of the most important brands under Gilead's umbrella include Truvada, a cornerstone drug for the treatment of HIV and pre-exposure prophylaxis (PrEP). Harvoni and Sovaldi are leading medications in the company's hepatitis C segment. Recently, Veklury (better known as remdesivir) gained significant attention as an antiviral medication for COVID-19. Additionally, Biktarvy is another prominent Gilead drug used in the management of HIV. Gilead Sciences' products and services have a significant global footprint, with the company operating in numerous countries across continents. The United States stands as a key market, alongside Europe, Asia, South America, and Africa. The company's market presence varies by region, adapting to local disease prevalence, regulatory environments, and healthcare systems. Gilead's extensive reach demonstrates its role as a major player in both developed and developing markets worldwide. (Powered by AI)

Show Company Information

Analytics based on the Sustainable Development Goals

Negative: 6 Positive: 7
12 Direct Scores
1 Peer-based Scores
384 Total Ratings

Materiality Map

Topics by SDG

Weight of score by SDG

Grid Table
SDG #Analyses Weight Impact Score
17: Partnership for the Goals 1 11.45% +2.97
16: Peace, Justice and Strong Institutions 1 7.77% -2.34
14: Life below Water 1 5.84% -2.77
13: Climate Action 1 5.93% -2.83
12: Responsible Consumption and Production 1 2.83% -1.77
10: Reduced Inequalities 1 3.28% +1.30
8: Decent work and Economic Growth 1 2.74% +3.27
6: Clean Water and Sanitation 1 2.29% -2.55
5: Gender Equality 1 7.50% +0.93
3: Good Health and Well-being 4 50.38% +3.17

Score Compared to Peer Group Average by SDG

Detailed Peer Group Comparison by SDG

SDG Peer Group Average
Gilead Sciences
GlaxoSmithKline
Novartis
Roche
Pfizer
Abbvie
SDG1Peer Group Average Gilead SciencesGlaxoSmithKlineNovartisRochePfizerAbbvie
1 --------
2 --------
9 --------
11 --------
14 -2.71>-2.77 -2.79-2.41-2.84-2.69-2.77
15 --------
7 --------
13 -3.28<-2.83 -3.62-3.45-3.65-3.43-2.69
5 +0.10<+0.93 +2.48-2.00+0.48+0.68-2.00
17 +2.46<+2.97 +2.50+1.98+2.48+2.60+2.20
8 +2.72<+3.27 +2.81+2.71+2.50+2.56+2.50
10 -0.48<+1.30 -1.86-0.30-0.27-1.14-0.60
6 -2.82<-2.55 -2.83-2.99-2.62-2.99-2.94
12 -2.49<-1.77 -2.78-2.88-2.50-2.99-2.01
4 --------
3 +2.51<+3.17 +2.16+2.98+2.58+2.39+1.80
16 -3.11<-2.34 -3.98-3.15-3.16-3.04-2.99